1. INTRODUCTION {#pbc26108-sec-0010}
===============

Intensification of therapy for infants with acute lymphoblastic leukemia (ALL) has resulted in fewer relapses, but at the cost of increased morbidity and death, especially during induction therapy.[1](#pbc26108-bib-0001){ref-type="ref"}, [2](#pbc26108-bib-0002){ref-type="ref"} Increased nonhematological toxicity during modern treatment strategies for infant ALL has been reported, but severe immunodeficiency persisting after therapy has not been described.

Immunodeficiencies are classified as acquired or primary (PID). Congenital T‐cell immunodeficiencies, defined as CD3^+^ less than 300 cells/μl,[3](#pbc26108-bib-0003){ref-type="ref"} are generally more severe, compared to other immunodeficiencies, since T‐cells also play a crucial role in the function of B‐cells, NK‐cells, and macrophages. Chemotherapy is known to induce an immunodeficiency state by significantly depleting T‐cells, as well as NK‐cells and B‐cells.[4](#pbc26108-bib-0004){ref-type="ref"}, [5](#pbc26108-bib-0005){ref-type="ref"} Usually, immune reconstitution begins after completing chemotherapy. In children, greater than 2 years of age, who received intense chemotherapy for treatment of high‐risk ALL, T‐cell recovery was complete 12--18 months after cessation of chemotherapy. In addition, the absolute CD3^+^ count at 1 month was greater than 300 cells/μl in these patients.[5](#pbc26108-bib-0005){ref-type="ref"}, [6](#pbc26108-bib-0006){ref-type="ref"}

We describe five children who completed treatment for infantile ALL and soon after were diagnosed with persistent severe T‐cell, non‐HIV, immunodeficiency, with varying B‐cell and NK‐cell depletion, resulting in severe infections causing death in four and successful hematopoietic stem cell transplantation (HSCT) in one. The immune deficiency appeared to be secondary to their therapy. Our report highlights the importance of considering this complication in patients with infant ALL post chemotherapy.

2. RESULTS {#pbc26108-sec-0020}
==========

The IWK Health Centre Research Ethics Board reviewed this manuscript and provided a letter of support. We collected data on five infant cases, four females and one male, treated at three centers in North America between 1996 and 2015. Clinical and treatment characteristics are shown in Table [1](#pbc26108-tbl-0001){ref-type="table"}. None of the patients received experimental agents or HSCT during initial treatment. All patients completed protocol therapy. Most patients developed infections during treatment despite intravenous immunoglobulins and pneumocystis prophylaxis as per protocol guidelines.

###### 

Patient information pertaining to leukemia diagnosis and treatment

                                                                                    Patient A                                                                                                                            Patient B                                                                                                                                Patient C                                                                   Patient D                                               Patient E
  -------------------------------------- ------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------- --------------------------------------------- -----------------------------------------------------------------
  Diagnosis                                                                         MLL‐R ALL                                                                                                                            MLL‐R ALL                                                                                                                                MLL‐R ALL                                                             MLL nonrearranged ALL                                   MLL nonrearranged ALL
  Age at diagnosis                                                                 5 month old                                                                                                                          5 month old                                                                                                                              7 month old                                                                 8 month old                                            11 month old
  Treatment                                                  COG AALL0631[a](#pbc26108-tbl1-note-0002){ref-type="fn"}                                                                             COG AALL0631[b](#pbc26108-tbl1-note-0003){ref-type="fn"}                                                                                 COG AALL0631[b](#pbc26108-tbl1-note-0003){ref-type="fn"}                                           CCG 1953                                                CCG P9407
                                                                                 No Lestaurtanib                                                                                                                      No Lestaurtanib                                                                                                                          No Lestaurtanib                                                                                            
  Treatment course complications                                         Bacterial and fungal infections                                                                         Bacterial and viral infections, extensive thrombi involving upper venous system, enteritis                                                                                          None                                                          Bacterial and viral infections                Bacterial infections, chronic rhinorrhea/sinusitis
  Age at end of chemotherapy treatment                                             29 month old                                                                                                                         29 month old                                                                                                                             31 month old                                                               33 month old                                            24 month old
  Course after chemotherapy treatment     CMV viremia and cystitis, *Clostridium difficile* colitis, *Mycobacterium chelonae* cellulitis   Clostridium difficile colitis, oral herpes simplex virus, norovirus, bocavirus, rhinovirus, and HHV‐6 viremia, Enterobacter cloacae cystitis, pneumatosis intestinalis   *Mycobacterium chelonae* abscesses, parainfluenza‐3, coronavirus, CMV retinitis, *Candida esophagitis*   Pulmonary aspergillus, *Pseudomonas* sepsis   Parainfluenza type 3 sinusitis, HHV‐6 viremia, and encephalitis
  Age immunodeficiency confirmed                                                   31 month old                                                                                                                         31 month old                                                                                                                             44 month old                                                               36 month old                                            31 month old
  Therapy after ALL treatment                                                          None                                                                                                                            Interleukin‐7                                                                                                                                 HSCT                                                                       None                                                    HSCT
  Current age or age at death                                                31 month old (deceased)                                                                                                              35 month old (deceased)                                                                                                                  50 month old (deceased)                                                     37 month old (deceased)                                   8‐year‐old (alive)
  Autopsy results                                    Disseminated aspergillosis; severe thymic involution; lymphoid depletion                                                              Diffuse bronchopneumonia; severe thymic involution, lymphoid depletion                                                                                          Diffuse alveolar damage                                                      Autopsy not performed                                      Not applicable

ALL, acute Lymphoblastic leukemia; MLL, mixed lineage leukemia gene; MLL‐R, MLL rearranged; COG, Children\'s Oncology Group; CCG, Children\'s Cancer Study Group; HSCT, hematopoietic stem cell transplant. CMV, cytomegalovirus; HHV‐6, human herpesvirus 6.

Treated before induction amendments.

Treated after induction amendments (elimination of cyclophosphamide 1 g/m^2^).

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

All patients were healthy with no hospital admissions prior to the diagnosis of ALL, except Patient E had a history of urinary tract infections, acute otitis media, and chronic rhinorrhea. These infections did not require hospital admission or intravenous antibiotics. None of the patients had a family history that placed them at risk for PID, except patient B. Her parents were third cousins and from a First Nation\'s community in which children had previously been diagnosed with severe combined immunodeficiency (SCID), *RAG2* mutation, for which she tested negative. Patients A and C had normal newborn screening for SCID, using T‐cell receptor excision circle (TREC) assays. All patients were HIV‐negative before and after treatment.

After chemotherapy, patients were mildly to severely lymphopenic and developed recurrent or persistent infections. All were identified through formal immunology consultation to have a non‐HIV acquired immunodeficiency between 2 and 13 months, median 3 months, after completing chemotherapy (Table [2](#pbc26108-tbl-0002){ref-type="table"}). Three patients received additional therapy (one with interleukin‐7 \[IL‐7\] and two with HSCT) once the immunodeficiency was recognized. Unfortunately, four of the patients died with severe infections. Patient E was successfully treated with an unconditioned 10/10 HLA‐matched unrelated donor HSCT.

###### 

Immunologic investigations assessing immune function and causes of immune deficiency

                                                                                    Patient A                             Patient B           Patient C        Patient D                                Patient E                                Normal range[7](#pbc26108-bib-0007){ref-type="ref"}, [8](#pbc26108-bib-0008){ref-type="ref"}, [9](#pbc26108-bib-0009){ref-type="ref"}
  ----------------------------------------------------------- ------------------------------------------------------ -------------------- ------------------ ------------- -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------
  Investigations at ALL diagnosis                                                                                                                                                                                                               
  ALC (cells/μl)                                                                      14,600                                12,700                0               n/a                                      n/a                                                                                               3,400--9,000
  IgG (g/l)                                                                            5.61                                  2.15                8.27             n/a                                      n/a                                                                                                 2.4--8.8
  Abnormal viral serology                                               CMV IgM positive, CMV IgG positive             EBV IgG positive    CMV PCR positive       n/a                                      None                                 
  Investigations after completion of chemotherapy treatment                                                                                                                                                                                     
  Time since completion of chemotherapy treatment                                    2 months                              2 months           13 months        3 months                                  7 months                               
  ANC (cells/μl)                                                                      2,389                                 2,400                882            21,597                                    4,290                                                                                              2,000--7,100
  ALC (cells/μl)                                                                       210                                  1,400                 82              n/a                                     1,670                                                                                              2,300--5,400
  CD3^+^ (cells/μl)                                            82 (39%[a](#pbc26108-tbl2-note-0002){ref-type="fn"})        14 (1%)             25 (38%)       n/a (1.7%)                               \<17 (\<1%)                                                                                      1,400--3,700 (56--75%)
  CD4^+^ (cells/μl)                                                                   4 (2%)                               14 (1%)           \<20 (\<1%)      n/a (0.5%)                               \<17 (\<1%)                                                                                       700--2,200 (28--47%)
  CD8^+^ (cells/μl)                                                                  67 (32%)                               0 (0%)             23 (35%)       n/a (0.7%)                               \<17 (\<1%)                                                                                       490--1,300 (16--30%)
  CD19^+^ (cells/μl)                                                                23 (11% )                            1,065 (74%)         \<20 (\<1%)      n/a (1.6%)                              1,486 (89.9%)                                                                                      390--1,400 (14--33%)
  CD56^+^ (cells/μl)                                                                84 (40% )                             187 (13%)            41 (62%)       n/a (93.7%)                              167 (10.1%)                                                                                         130--720 (4--17%)
  IgG (g/l)                                                                            4.91                                  2.07                2.89            2.13                                     \<0.33                                                                                               7.1--11.6
  Other                                                                            TRECs normal                       *RAG2* gene normal     TRECs normal        None       *IL7RA*, *JAK3, DCLRE1C*, *ADA* genes and PNP activity, all normal  

ALL, acute lymphoblastic leukemia; ALC, absolute lymphocyte count; IgG, immunoglobulin G; CMV, cytomegalovirus; EBV, Epstein‐Barr Virus; PCR, polymerase change reaction; IgM, immunoglobulin M; TREC, T‐cell receptor excision circles; *RAG2, IL7RA, JAK3, DCLRE1C*, and *ADA* are common mutations that cause severe combined immunodeficiency; PNP, purine nucleoside phosphorylase deficiency; n/a, information not available.

Percentage of absolute lymphocyte count.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

3. DISCUSSION {#pbc26108-sec-0030}
=============

We describe the first report of non‐HIV, persistent T‐cell immunodeficiency, with varying B‐cell and NK‐cell depletion, in patients with infant ALL following modern intensive chemotherapy. Patients in our cohort remained mildly to severely lymphopenic and flow cytometry demonstrated extremely low CD3^+^, CD4^+^, and CD8^+^ T‐cell populations consistent with a severe T‐cell immunodeficiency despite completion of their chemotherapy treatment 2--13 months prior. We believe it is very unlikely that our patients had unrecognized PID. None of these patients had strong identifiers of PID, such as failure to thrive or intravenous antimicrobial use prior to ALL diagnosis.[10](#pbc26108-bib-0010){ref-type="ref"} Patient B did have a distant family history of RAG2 deficiency but she did not carry this mutation. Investigations prior to starting chemotherapy suggested patients A, B, and C had been exposed to viral infections with no major complications. Finally, Patient E had an extensive genetic workup excluding common SCID mutations and Patients A and C had normal TREC assays. Based on the described history and investigations, we concluded these were secondary immunodeficiencies produced by the chemotherapy.

Studies of immune reconstitution in children who received chemotherapy for hematologic malignancy demonstrate that in most children total lymphocyte count recovered within 3--6 months.[11](#pbc26108-bib-0011){ref-type="ref"} The total B‐cell count is normal in most children by 1 month and all children by 6 months after chemotherapy cessation.[6](#pbc26108-bib-0006){ref-type="ref"} NK‐cells were initially thought to totally recover within 1 month of cessation, but more recent studies have shown a delayed drop that may take 6--12 months to fully recover.[6](#pbc26108-bib-0006){ref-type="ref"}, [12](#pbc26108-bib-0012){ref-type="ref"}, [13](#pbc26108-bib-0013){ref-type="ref"}

As for the T‐cells, recovery of the CD4^+^ subset has been shown to have a direct relationship to the intensity of therapy and an inverse relationship with age.[14](#pbc26108-bib-0014){ref-type="ref"} This inverse relationship is thought to be because CD4^+^ T‐cells recover more rapidly through a thymic‐dependent pathway. Normal thymic involution does not begin until approximately 7 years of age.[4](#pbc26108-bib-0004){ref-type="ref"} Thymic enlargement post chemotherapy has been demonstrated in pediatric patients.[6](#pbc26108-bib-0006){ref-type="ref"} In most children treated for standard‐risk and high‐risk ALL, CD4^+^, and CD8^+^ T‐cells require 3--18 months to recover and the CD3^+^ count at 1 month was greater than 300 cells/μl regardless of treatment intensity.[5](#pbc26108-bib-0005){ref-type="ref"}, [6](#pbc26108-bib-0006){ref-type="ref"} Despite these prolonged impairments in immune function, severe opportunistic infections are not typically appreciated after cessation of chemotherapy, and death from infection is rare.[13](#pbc26108-bib-0013){ref-type="ref"} These T‐cell recovery patterns were not seen in our patients.

In addition, cyclophosphamide and cytarabine have been associated with depletion of early lineage T‐cells, thus affecting T‐cell proliferation.[15](#pbc26108-bib-0015){ref-type="ref"} Although Patient A was treated prior to cyclophosphamide being eliminated from AALL0631 induction, all of our patients were exposed to cumulative cyclophosphamide doses at least double that of standard‐risk or high‐risk ALL protocols used in older children.[1](#pbc26108-bib-0001){ref-type="ref"} It is possible that these higher doses of cyclophosphamide (and cytarabine exposure) contributed to poor T‐cell recovery. None of the studies examining immune reconstitution after chemotherapy have focused on infants; thus the pattern of immune recovery compared to older children is unknown.

All of our patients had severe T‐cell deficiency with a CD3^+^ count less than 100 cells/μl, despite some being only mildly lymphopenic. The patients who underwent autopsy were found to have profound thymic involution, suggesting damage to the thymus, which likely contributed to poor T‐cell recovery. Patient B was treated with IL‐7 because of previous reports in patients post‐HSCT or with HIV that CD4^+^ T‐cells recovered with IL‐7 therapy.[16](#pbc26108-bib-0016){ref-type="ref"}, [17](#pbc26108-bib-0017){ref-type="ref"}, [18](#pbc26108-bib-0018){ref-type="ref"}, [19](#pbc26108-bib-0019){ref-type="ref"} Unfortunately, despite this treatment, her T‐cells showed no signs of recovery.

These are the first reported cases of non‐HIV, severe, persistent T‐cell immunodeficiency, with varying B‐cell and NK‐cell depletion, secondary to infant ALL chemotherapy. These children may benefit from preemptive and aggressive infection management and/or require therapies to assist with immune reconstitution, such as HSCT. However, the prevalence of this complication is unknown. Formal evaluation to identify abnormal T‐cell recovery should be considered in all patients with infant ALL following modern intensive chemotherapy protocols.

ALL

:   acute lymphoblastic leukemia

HSCT

:   hematopoietic stem cell transplantation

PID

:   primary immunodeficiency

SCID

:   severe combined immunodeficiency

TREC

:   T‐cell receptor excision circle
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